Related Experiment Video
Updated: May 3, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 5, 2010
Biologic therapies for severe asthma with type 2 inflammation: current evidence, patient selection, and future
1Department of Intellectual Property Rights, Research and Development Cell, Lovely Professional University, Phagwara, India.
Objective:
Recent advancements in biologic therapies have revolutionized the treatment landscape for allergic asthma by improving patient outcomes through targeted immune modulation. This review synthesizes contemporary clinical evidence, evaluates criteria for optimal patient selection, examines safety considerations, and highlights future therapeutic directions for managing severe allergic asthma.
Methods:
A systematic literature search was conducted across major medical databases, including PubMed, Embase, and Cochrane, up to 2025. The search prioritized randomized controlled trials, meta-analyses, and real-world studies involving biologic agents targeting immunoglobulin E (IgE) and key type 2 inflammatory pathways. Studies were selected based on relevance to efficacy, safety, and personalized clinical application of agents such as omalizumab, IL-5 antagonists, dupilumab, and tezepelumab, with emphasis on biomarker-guided precision medicine approaches.
Results:
Evidence demonstrates that biologic therapies significantly reduce asthma exacerbations, hospital admissions, and reliance on systemic corticosteroids while improving lung function and quality of life. Biomarkers including blood eosinophil counts, serum IgE, and fractional exhaled nitric oxide (FeNO) enhance therapeutic selection and response prediction. Despite substantial clinical benefits, challenges remain regarding accessibility, cost, and long-term safety data. Emerging biologics and combination strategies show promise for further improving outcomes.
Conclusions:
Biologic agents targeting type 2 inflammation represent a paradigm shift in allergic asthma management. Personalized treatment strategies maximize clinical benefits; however, continued research is required to refine patient selection, address healthcare disparities, and expand therapeutic options.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:13Asthma III: Clinical Manifestations